Circle Pharma, a South San Francisco, CA-based macrocycle drug discovery and development company focused on intractable cancer targets, raised $45m in Series B financing.

The round was led by The Column Group, with participation from Nextech Invest and existing investors ShangPharma, LifeForce Capital, and the Berkeley Catalyst Fund.

In conjunction with the financing, Peter Svennilson, founder and managing partner of The Column Group, and Thilo Schroeder, Ph.D., partner at Nextech Invest joined the board.

Led by David J. Earp, J.D., Ph.D., President and CEO, Circle is developing a new paradigm for macrocycle drug discovery based on rational design and synthetic chemistry.

Its macrocycle development platform is applicable across a wide range of serious diseases. | To read full story, visit https://startuparound.com/read/1584480607.7001383/Circle-Pharma-Raises-$45m-in-Series-B-Financing?ref=audio_experience